Neha Krishnamohan - 13 Nov 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Director
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Neha Krishnamohan
Issuer symbol
ARQT
Transactions as of
13 Nov 2025
Transactions value $
-$614,263
Form type
4
Filing time
17 Nov 2025, 19:56:39 UTC
Previous filing
16 Jun 2025
Next filing
17 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Krishnamohan Neha Director C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Latha Vairavan, as Attorney-in-Fact for Neha Krishnamohan 17 Nov 2025 0001866171

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Options Exercise $233K +27.1K +115.83% $8.63 50.4K 13 Nov 2025 Direct F1
transaction ARQT Common Stock Options Exercise $91.8K +12.2K +24.24% $7.51 62.6K 13 Nov 2025 Direct F1
transaction ARQT Common Stock Sale -$911K -39.3K -62.71% $23.19 23.4K 13 Nov 2025 Direct F1, F2
transaction ARQT Common Stock Sale -$28.8K -1.23K -5.28% $23.37 22.1K 13 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Options Exercise $0 -27.1K -100% $0.00 0 13 Nov 2025 Common Stock 27.1K $8.63 Direct F1, F3
transaction ARQT Stock Option (right to buy) Options Exercise $0 -12.2K -100% $0.00 0 13 Nov 2025 Common Stock 12.2K $7.51 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 14, 2025, by the Reporting Person, with a plan end date of November 2, 2026.
F2 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F4 The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023.